Profile

JN Nova's Two JN2019 Development Leads: A novel Long COVID therapeutic is scheduled to enter clinical trials in Q1 2026. The lead candidate is designed to protect against the deleterious pulmonary effects associated with idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and acute kidney injury (AKI). JN Nova Pharma is actively seeking a global co-development partner to accelerate the advancement of this promising therapeutic.

JN Nova Pharma Inc. logo

Website

jnnova.com

Contact


Event details

Date: December 1 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

13 in total